RichardClarkRichard Clark, Merck's chief executive, says, "We believe we can be the leaders" in the follow-on biologics field based on the GlycoFi technology.

FORBES

Richard Clark , Merck's chief executive, says, "We believe we can be the leaders" in the follow-on biologics field based on the GlycoFi technology.

FORBES: Big Pharma

Therefore, as the name implies, all new generic biological drugs, also called "biosimilars" or "follow-on biologics, " will be similar--but not identical--to the original drugs.

FORBES: Magazine Article